More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The pharmaceutical industry as a whole historically has had weaker working-capital performance comparative to other industries, but it is a key strategic goal overall for pharma companies and for sourcing and procurement organizations to improve...

Biosimilars are a small part of the overall market for biologics, which accounted for $277 billion in sales globally in 2017 and is projected to reach $452 billion by 2022. The European Union leads with biosimilar approvals comparative to the US,...

Orphan drugs represent a niche sector in the global pharmaceutical market, but have accounted for approximately 40% of new drug approvals in the US over the past three years. Traditionally the focus of smaller innovator companies, the...

The pharmaceutical industry is on a record-setting pace for approvals of new molecular entities (NMEs) in 2018. Through early November, the FDA had approved 48 NMEs, already outpacing 2017’s recent high of 46 NME approvals and nearing the high mark...

Drug pricing took center stage once again with a proposal by US Department of Health and Human Services Secretary Alex Azar to require drug companies in the US, for the first time ever, to include in their TV advertising the list price of any drug...

A recent analysis by Deloitte of 400 CEOs and board members from US organizations with $1 billion or more in annual revenues examines executives views on four critical strategic risks, including the extended enterprise involving third-party...

In what market segments are contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) expanding? DCAT Value Chain Insights highlights key activity in drug-substance and drug-product development...

A recent analysis by Ernst & Young (EY) of 2,600 executives shows that although 2018 is on track to become a near-record year for the number of global mergers and acquisitions (M&A), corporate acquisition appetite is at a four-year low. How...

Pfizer announced that Ian Read, current Chairman and CEO of Pfizer will step down as CEO January 1, 2019 to be succeeded as CEO by Albert Bourla, the company’s current chief operating officer. Does the changing of the guard mean a shift in...